A comparison of prostate cancer detection rates between TRUS-GB and MRI-GB: a systematic review and meta-analysis
Authors:
Open Access
- 12 January 2026
- journal article
- review article
- Published by Springer Nature in African Journal of Urology
- Vol. 32 (1) , 2
Abstract
Background: Prostate cancer (PCa) is one of the most common cancers in men and a major cause of cancer-related death. Accurate diagnosis is essential to identify clinically significant cases while avoiding overdiagnosis. Traditionally, prostate biopsies are performed as systematic sampling using transrectal ultrasound guidance (systematic TRUS-GB), whereas lesion-targeted multiparametric magnetic resonance imaging–guided biopsy (lesion-targeted mpMRI-GB) has emerged as a promising alternative. While lesion-targeted mpMRI-GB may improve cancer detection, its clinical advantage over systematic TRUS-GB remains debated. This meta-analysis compares the detection rates of PCa between lesion-targeted mpMRI-GB and systematic TRUS-GB in biopsy-naive patients. Main body: We systematically searched PubMed, Cochrane Central, Scielo, and LILACS for studies comparing lesion-targeted mpMRI-GB to systematic TRUS-GB in biopsy-naive patients suspected of having PCa. Outcomes included the detection rate of overall PCa, clinically significant PCa, clinically insignificant PCa, and missed diagnoses. We included 9,165 patients from 14 studies, of which three were randomized controlled trials (RCTs). lesion-targeted mpMRI-GB was used to diagnose overall PCa in 4,349 (47,45%) patients. The cancer detection rate of overall PCa (RR 1.26; 95% CI 1.02–1.55; p < 0.00001; i² = 95%) and clinically significant PCa (RR 1.46; 95% CI 1.11–1.93; p = 0.007; i² = 93%) were significantly higher in patients diagnosed with lesion-targeted mpMRI-GB. The detection rate of clinically insignificant cancer (RR 0.85; CI 0.64–1.13; p = 0.25; I² = 77%) was not statistically significant. However, missed diagnoses were lower in the systematic TRUS-GB group, showing a potential difference. Subgroup analysis was evaluated. Conclusions: Using lesion-targeted mpMRI-GB as a first-line approach increases the likelihood of detecting clinically significant prostate cancer. However, lesion-targeted mpMRI-GB has not demonstrated clear superiority over systematic TRUS-GB in reducing missed diagnoses, suggesting that the choice of technique should be individualized or that a combined biopsy strategy may be considered.Keywords
This publication has 29 references indexed in Scilit:
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2023
- Magnetic Resonance Imaging–targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate CancerEuropean Urology Open Science, 2022
- A prospective multi-center randomized comparative trial evaluating outcomes of transrectal ultrasound (TRUS)-guided 12-core systematic biopsy, mpMRI-targeted 12-core biopsy, and artificial intelligence ultrasound of prostate (AIUSP) 6-core targeted biopsy for prostate cancer diagnosisWorld Journal of Urology, 2022
- A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging–directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve MenEuropean Urology, 2022
- Comparison of Multiparametric Magnetic Resonance Imaging–Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate CancerJAMA Oncology, 2021
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2021
- Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical StudyEuropean Urology, 2019
- Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching AnalysisClinical Genitourinary Cancer, 2019
- Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?European Urology, 2018
- Prostate cancer detection with magnetic resonance‐ultrasound fusion biopsy: The role of systematic and targeted biopsiesCancer, 2016